S&P 500   4,273.80 (-0.20%)
DOW   33,594.50 (-0.50%)
QQQ   354.59 (-0.02%)
AAPL   178.34 (-1.44%)
MSFT   336.58 (+0.35%)
META   270.97 (-0.60%)
GOOGL   125.96 (+1.03%)
AMZN   124.94 (+0.56%)
TSLA   215.32 (+0.63%)
NVDA   389.34 (-1.00%)
NIO   7.69 (+1.72%)
BABA   84.16 (-0.13%)
AMD   118.19 (+0.28%)
T   15.42 (+1.38%)
F   12.56 (+1.37%)
MU   67.74 (-2.07%)
CGC   0.78 (-5.11%)
GE   104.64 (-1.10%)
DIS   90.94 (+0.19%)
AMC   4.57 (+0.44%)
PFE   38.61 (+0.65%)
PYPL   64.52 (+0.88%)
NFLX   402.59 (+0.53%)
S&P 500   4,273.80 (-0.20%)
DOW   33,594.50 (-0.50%)
QQQ   354.59 (-0.02%)
AAPL   178.34 (-1.44%)
MSFT   336.58 (+0.35%)
META   270.97 (-0.60%)
GOOGL   125.96 (+1.03%)
AMZN   124.94 (+0.56%)
TSLA   215.32 (+0.63%)
NVDA   389.34 (-1.00%)
NIO   7.69 (+1.72%)
BABA   84.16 (-0.13%)
AMD   118.19 (+0.28%)
T   15.42 (+1.38%)
F   12.56 (+1.37%)
MU   67.74 (-2.07%)
CGC   0.78 (-5.11%)
GE   104.64 (-1.10%)
DIS   90.94 (+0.19%)
AMC   4.57 (+0.44%)
PFE   38.61 (+0.65%)
PYPL   64.52 (+0.88%)
NFLX   402.59 (+0.53%)
S&P 500   4,273.80 (-0.20%)
DOW   33,594.50 (-0.50%)
QQQ   354.59 (-0.02%)
AAPL   178.34 (-1.44%)
MSFT   336.58 (+0.35%)
META   270.97 (-0.60%)
GOOGL   125.96 (+1.03%)
AMZN   124.94 (+0.56%)
TSLA   215.32 (+0.63%)
NVDA   389.34 (-1.00%)
NIO   7.69 (+1.72%)
BABA   84.16 (-0.13%)
AMD   118.19 (+0.28%)
T   15.42 (+1.38%)
F   12.56 (+1.37%)
MU   67.74 (-2.07%)
CGC   0.78 (-5.11%)
GE   104.64 (-1.10%)
DIS   90.94 (+0.19%)
AMC   4.57 (+0.44%)
PFE   38.61 (+0.65%)
PYPL   64.52 (+0.88%)
NFLX   402.59 (+0.53%)
S&P 500   4,273.80 (-0.20%)
DOW   33,594.50 (-0.50%)
QQQ   354.59 (-0.02%)
AAPL   178.34 (-1.44%)
MSFT   336.58 (+0.35%)
META   270.97 (-0.60%)
GOOGL   125.96 (+1.03%)
AMZN   124.94 (+0.56%)
TSLA   215.32 (+0.63%)
NVDA   389.34 (-1.00%)
NIO   7.69 (+1.72%)
BABA   84.16 (-0.13%)
AMD   118.19 (+0.28%)
T   15.42 (+1.38%)
F   12.56 (+1.37%)
MU   67.74 (-2.07%)
CGC   0.78 (-5.11%)
GE   104.64 (-1.10%)
DIS   90.94 (+0.19%)
AMC   4.57 (+0.44%)
PFE   38.61 (+0.65%)
PYPL   64.52 (+0.88%)
NFLX   402.59 (+0.53%)
NASDAQ:CSTL

Castle Biosciences (CSTL) Stock Forecast, Price & News

$11.37
-11.36 (-49.98%)
(As of 03:16 PM ET)
Compare
Today's Range
$9.26
$17.87
50-Day Range
$21.05
$26.00
52-Week Range
$9.26
$36.10
Volume
7.63 million shs
Average Volume
225,717 shs
Market Capitalization
$303.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.67

Castle Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
237.0% Upside
$40.57 Price Target
Short Interest
Healthy
3.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Castle Biosciences in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.01 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.60) to ($2.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

229th out of 980 stocks

Medical Laboratories Industry

6th out of 22 stocks


CSTL stock logo

About Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CSTL Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Why Shares of Castle Biosciences Slumped This Week
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Analyst Expectations for Castle Biosciences's Future
See More Headlines

CSTL Price History

CSTL Company Calendar

Last Earnings
5/03/2023
Today
6/05/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CSTL
Fax
N/A
Employees
342
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.57
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+271.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-67,140,000.00
Pretax Margin
-48.35%

Debt

Sales & Book Value

Annual Sales
$137.04 million
Book Value
$15.15 per share

Miscellaneous

Free Float
24,636,000
Market Cap
$320.81 million
Optionable
Not Optionable
Beta
1.01

Key Executives

  • Derek J. MaetzoldDerek J. Maetzold
    President, Chief Executive Officer & Director
  • Kristen M. OelschlagerKristen M. Oelschlager
    Chief Operating Officer
  • Franklin Michael Stokes
    Chief Financial Officer
  • Robert W. Cook
    Senior Vice President-Research & Development
  • Matthew Goldberg
    Medical Director













CSTL Stock - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings
or view top-rated stocks.

What is Castle Biosciences' stock price forecast for 2023?

4 equities research analysts have issued 12-month price targets for Castle Biosciences' stock. Their CSTL share price forecasts range from $25.00 to $54.00. On average, they predict the company's share price to reach $40.57 in the next year. This suggests a possible upside of 237.5% from the stock's current price.
View analysts price targets for CSTL
or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2023?

Castle Biosciences' stock was trading at $23.54 at the start of the year. Since then, CSTL stock has decreased by 48.9% and is now trading at $12.02.
View the best growth stocks for 2023 here
.

Are investors shorting Castle Biosciences?

Castle Biosciences saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 878,100 shares, a decline of 11.0% from the April 30th total of 986,400 shares. Based on an average daily volume of 145,300 shares, the short-interest ratio is currently 6.0 days.
View Castle Biosciences' Short Interest
.

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CSTL earnings forecast
.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) issued its earnings results on Wednesday, May, 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.30. The business had revenue of $42.04 million for the quarter, compared to the consensus estimate of $37.63 million. Castle Biosciences had a negative trailing twelve-month return on equity of 17.74% and a negative net margin of 47.11%.

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $170.00 million-$180.00 million, compared to the consensus revenue estimate of $173.41 million.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an initial public offering on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (11.16%), BlackRock Inc. (7.94%), Principal Financial Group Inc. (4.82%), Granahan Investment Management LLC (4.50%), Kornitzer Capital Management Inc. KS (2.43%) and Palisade Capital Management LP (2.16%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends
.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $12.02.

How much money does Castle Biosciences make?

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $320.81 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis.

How many employees does Castle Biosciences have?

The company employs 342 workers across the globe.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.

This page (NASDAQ:CSTL) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -